✦ LIBER ✦

Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations

✍ Scribed by F. Grossi; A. Brianti; C. Defferrari; P. Pronzato

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of efficacy and toxicity betw

✍ Meiqi Shi; Bo Shen; Guochun Cao; Yun Zeng; Guohao Xia; Jifeng Feng; Lin Xu 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 80 KB

A phase II trial of weekly chemotherapy

✍ Kiyoshi Mori; Hiroyuki Kobayashi; Yukari Kamiyama; Yasuhiko Kano; Tetsuro Kodama 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 268 KB

Gemcitabine plus docetaxel as first-line

✍ Joaquín Casal; Margarita Amenedo; José Ramón Mel; Luis Miguel Antón; Rubén Rodrí 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 343 KB

Comparative cost-minimisation of oral an

✍ K. Le Lay; E. Myon; S. Hill; L. Riou-Franca; D. Scott; M. Sidhu; D. Dunlop; R. L 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 170 KB

The clinical evaluation of Iressa first-

✍ Xiuhua Sun; Yang Zhang; Xian Zhang; Jing Yu; Yinghua Li; Xiaoyan Yang; Zhaoxia D 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 76 KB

Ifosfamide, cisplatin, vinblastine combi

✍ Hiroshi Saito; Kaoru Shimokata; Masashi Yamamoto; Hideo Saka; Shuzo Sakai; Hidea 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 214 KB